Michael W. Dunne
2017
In 2017, Michael W. Dunne earned a total compensation of $603.7K as Chief Scientific Officer at Iterum Therapeutics plc.
Compensation breakdown
| Non-Equity Incentive Plan | $154,350 |
|---|---|
| Option Awards | $78,078 |
| Salary | $367,500 |
| Other | $3,741 |
| Total | $603,669 |
Dunne received $367.5K in salary, accounting for 61% of the total pay in 2017.
Dunne also received $154.4K in non-equity incentive plan, $78.1K in option awards and $3.7K in other compensation.
Rankings
In 2017, Michael W. Dunne's compensation ranked 11,170th out of 14,666 executives tracked by ExecPay. In other words, Dunne earned more than 23.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,170 out of 14,666 | 24th |
Division Manufacturing | 4,373 out of 5,772 | 24th |
Major group Chemicals And Allied Products | 1,584 out of 2,075 | 24th |
Industry group Drugs | 1,304 out of 1,731 | 25th |
Industry Pharmaceutical Preparations | 1,018 out of 1,333 | 24th |
Source: SEC filing on April 25, 2019.
Dunne's colleagues
We found two more compensation records of executives who worked with Michael W. Dunne at Iterum Therapeutics plc in 2017.